Literature DB >> 20683713

Vertebral fractures in Gaucher disease type I: data from the French "Observatoire" on Gaucher disease (FROG).

R-M Javier1, E Hachulla, C Rose, V Gressin, P Chérin, E Noël, C de Roux-Serratrice, D Dobbelaere, A Hartmann, R Jaussaud, P Clerson, B Grosbois, C Roux.   

Abstract

UNLABELLED: Gaucher disease type 1 (GD1), results in a range of skeletal complications including osteopenia, osteoporosis, and osteonecrosis, but there is little published information regarding vertebral fractures. Findings from this observational study indicated that the prevalence of vertebral fractures in a cohort of adult French GD1 patients is approximately 15%.
INTRODUCTION: The aim of the study was to assess the prevalence and characteristics of vertebral fractures in a cohort of adult patients with GD1.
METHODS: This study was performed in adult patients with GD1 based on a detailed and complete clinical examination. For all patients for whom vertebral fractures were reported, a specific questionnaire was sent to physicians, and imaging data were collected, when available, for centralized analysis.
RESULTS: Data were collected from a total of 105 adult GD1 patients. Bone complications were reported in 85% of patients, among whom vertebral fractures were diagnosed in 16 (15%); seven women and nine men (mean age, 45 years). We observed five patients with multiple vertebral fractures and one patient in whom the T3 vertebra was fractured. Most of these patients did not report fracture-related back pain.
CONCLUSIONS: The prevalence of vertebral fractures in this cohort of adult patients with GD1 was 15%. Greater awareness of the natural history of vertebral fractures in GD1, and rigorous monitoring of bone fragility and spine involvement in affected patients, should allow earlier detection and initiation of treatment tailored toward improving bone status.

Entities:  

Mesh:

Year:  2010        PMID: 20683713     DOI: 10.1007/s00198-010-1342-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  32 in total

1.  Surgical management of spinal involvement in children and adolescents with Gaucher's disease.

Authors:  M S Kocher; J E Hall
Journal:  J Pediatr Orthop       Date:  2000 May-Jun       Impact factor: 2.324

Review 2.  Severe pathologic compression of three consecutive vertebrae in Gaucher's disease: a case report and review of the literature.

Authors:  L Wiesner; O Niggemeyer; R Kothe; L Meiss
Journal:  Eur Spine J       Date:  2002-05-24       Impact factor: 3.134

3.  Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy.

Authors:  Maaike de Fost; Carel J M van Noesel; Johannes M F G Aerts; Mario Maas; Ruud G Pöll; Carla E M Hollak
Journal:  Haematologica       Date:  2008-06-02       Impact factor: 9.941

4.  Spinal cord decompression for Gaucher's disease.

Authors:  J Goldblatt; P Keet; D Dall
Journal:  Neurosurgery       Date:  1987-08       Impact factor: 4.654

Review 5.  Bone complications in children with Gaucher disease.

Authors:  B Bembi; G Ciana; E Mengel; M R Terk; C Martini; R J Wenstrup
Journal:  Br J Radiol       Date:  2002       Impact factor: 3.039

6.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

7.  Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.

Authors:  Hans Andersson; Paige Kaplan; Katherine Kacena; John Yee
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

8.  Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.

Authors:  Gregory M Pastores; Deborah Elstein; Martin Hrebícek; Ari Zimran
Journal:  Clin Ther       Date:  2007-08       Impact factor: 3.393

9.  Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy.

Authors:  Richard J Wenstrup; Laurie Bailey; Gregory A Grabowski; Jay Moskovitz; Alan E Oestreich; Wei Wu; Shumei Sun
Journal:  Blood       Date:  2004-03-09       Impact factor: 22.113

10.  Skeletal complications of Gaucher disease.

Authors:  D W Stowens; S L Teitelbaum; A J Kahn; J A Barranger
Journal:  Medicine (Baltimore)       Date:  1985-09       Impact factor: 1.889

View more
  2 in total

Review 1.  Gaucher Disease in Bone: From Pathophysiology to Practice.

Authors:  Derralynn Hughes; Peter Mikosch; Nadia Belmatoug; Francesca Carubbi; TimothyM Cox; Ozlem Goker-Alpan; Andreas Kindmark; PramodK Mistry; Ludger Poll; Neal Weinreb; Patrick Deegan
Journal:  J Bone Miner Res       Date:  2019-06-24       Impact factor: 6.741

2.  The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.

Authors:  Patrick Deegan; Aneal Khan; José Simon Camelo; Julie L Batista; Neal Weinreb
Journal:  Orphanet J Rare Dis       Date:  2021-02-18       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.